The nitric oxide donor molsidomine rescues cardiac function in rats with chronic kidney disease and cardiac dysfunction

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 6, 2010, Pages

  Bongartz, Lennart G ^a   Braam, Branko ^b   Verhaar, Marianne C ^a   Cramer, Maarten Jan M ^a   Goldschmeding, Roel ^a   Gaillard, Carlo A ^c   Steendijk, Paul ^d   Doevendans, Pieter A ^a   Joles, Jaap A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MEANDER MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hemodynamics; Left ventricular systolic dysfunction; Rescue therapy

Indexed keywords

CREATININE; DRUG VEHICLE; MOLSIDOMINE; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLE; HEART DISEASE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE VOLUME; HEART STROKE VOLUME; HISTOLOGY; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CREATININE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; KIDNEY DISEASES; MALE; MOLSIDOMINE; MYOCARDIAL CONTRACTION; MYOCARDIUM; NEPHRECTOMY; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROARGININE; RATS; RATS, INBRED LEW; STROKE VOLUME; TIME FACTORS; TYROSINE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 78649729928     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00400.2010     Document Type: Article

References (48)

1. Attia DM, Ni ZN, Boer P, Attia MA, Goldschmeding R, Koomans HA, Vaziri ND, Joles JA. Proteinuria is preceded by decreased nitric oxide synthesis and prevented by a NO donor in cholesterol-fed rats. Kidney Int 61: 1776-1787, 2002.
2. Bassenge E, Mulsch A. Anti-ischemic actions of molsidomine by venous and large coronary dilatation in combination with antiplatelet effects. J Cardiovasc Pharmacol 14, Suppl 11: S23-S28, 1989.
3. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 294: F1-F9, 2008.
4. Bendall JK, Damy T, Ratajczak P, Loyer X, Monceau V, Marty I, Milliez P, Robidel E, Marotte F, Samuel JL, Heymes C. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in β-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation 110: 2368-2375, 2004.
5. Benigni A, Zoja C, Noris M, Corna D, Benedetti G, Bruzzi I, Todeschini M, Remuzzi G. Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis 33: 746-753, 1999.
6. Bidani AK, Schwartz MM, Lewis EJ. Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol Renal Fluid Electrolyte Physiol 252: F1003-F1010, 1987.
7. Bohle A, Mackensen-Haen S, von Gise H. Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution. Am J Nephrol 7: 421-433, 1987.
8. Bongartz LG, Braam B, Verhaar MC, Cramer MJ, Goldschmeding R, Gaillard CA, Doevendans PA, Joles JA. Transient nitric oxide reduction induces permanent cardiac systolic dysfunction and worsens kidney damage in rats with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 298: R815-R823, 2010.
9. Bongartz LG, Braam B, Verhaar MC, Cramer MJ, Goldschmeding R, Gaillard GA, Doevendans PA, Joles JA. The nitric oxide (NO) donor molsidomine rescues heart function in experimental cardiorenal failure (Abstract). Circulation 118: S-336, 2008.
10. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: "Guyton revisited". Eur Heart J 26: 11-17, 2005.
11. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 289: H501-H512, 2005.
12. Buys ES, Raher MJ, Blake SL, Neilan TG, Graveline AR, Passeri JJ, Llano M, Perez-Sanz TM, Ichinose F, Janssens S, Zapol WM, Picard MH, Bloch KD, Scherrer-Crosbie M. Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload. Am J Physiol Heart Circ Physiol 293: H620-H627, 2007.
13. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314: 1547-1552, 1986.
14. Cohn JN, Tam SW, Anand IS, Taylor AL, Sabolinski ML, Worcel M. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail 13: 331-339, 2007.
15. Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9: 872-878, 2007.
16. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 13: 599-608, 2007.
17. de Mattos AM, Siedlecki A, Gaston RS, Perry GJ, Julian BA, Kew CE 2nd, Deierhoi MH, Young C, Curtis JJ, Iskandrian AE. Systolic dysfunction portends increased mortality among those waiting for renal transplant. J Am Soc Nephrol 19: 1191-1196, 2008.
18. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol 358: 113-122, 1998.
19. Feelisch M, Ostrowski J, Noack E. On the mechanism of NO release from sydnonimines. J Cardiovasc Pharmacol 14, Suppl 11: S13-S22, 1989.
20. Gerova M, Kristek F. Efficiency of NO donors in substituting impaired endogenous NO production: a functional and morphological study. Physiol Res 50: 165-173, 2001.
21. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
22. Grocott-Mason R, Anning P, Evans H, Lewis MJ, Shah AM. Modulation of left ventricular relaxation in isolated ejecting heart by endogenous nitric oxide. Am J Physiol Heart Circ Physiol 267: H1804-H1813, 1994.
23. Grund E, Muller-Ruchholtz ER, Lapp ER, Losch HM, Lochner W. Comparative study of nitroglycerin and molsidomine. Effects on the integrated systemic venous bed and the arterial pressure in dogs. Arzneimittelforschung 28: 1624-1628, 1978.
24. Holtz J, Bassenge E, Kolin A. Hemodynamic and myocardial effects of long-lasting venodilation in the conscious dog: analysis of molsidomine in comparison with nitrates. Basic Res Cardiol 73: 469-481, 1978.
25. Koeners MP, Braam B, van der Giezen DM, Goldschmeding R, Joles JA. A perinatal nitric oxide donor increases renal vascular resistance and ameliorates hypertension and glomerular injury in adult fawn-hooded hypertensive rats. Am J Physiol Regul Integr Comp Physiol 294: R1847-R1855, 2008.
26. Kreutz R, Kovacevic L, Schulz A, Rothermund L, Ketteler M, Paul M. Effect of high NaCl diet on spontaneous hypertension in a genetic rat model with reduced nephron number. J Hypertens 18: 777-782, 2000.
27. Kristek F, Faberova V, Varga I. Long-term effect of molsidomine and pentaerythrityl tetranitrate on cardiovascular system of spontaneously hypertensive rats. Physiol Res 52: 709-717, 2003.
28. Lehmann G, Hahnel I, Reiniger G, Lampen M, Beyerle A, Schomig A. Infusions with molsidomine and isosorbide-5-mononitrate in congestive heart failure: mechanisms underlying attenuation of effects. J Cardiovasc Pharmacol 31: 212-220, 1998.
29. Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 89: 345-354, 1994.
30. Majid PA, DeFeyter PJ, Van der Wall EE, Wardeh R, Roos JP. Molsidomine in the treatment of patients with angina pectoris. N Engl J Med 302: 1-6, 1980.
31. Matter CM, Mandinov L, Kaufmann PA, Vassalli G, Jiang Z, Hess OM. Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. Circulation 99: 2396-2401, 1999.
32. McMahon AC, Vescovo G, Dalla Libera L, Wynne DG, Fluck RJ, Harding SE, Raine AE. Contractile dysfunction of isolated ventricular myocytes in experimental uraemia. Exp Nephrol 4: 144-150, 1996.
33. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.
34. Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 89: 2070-2078, 1994.
35. Raine AE, Seymour AM, Roberts AF, Radda GK, Ledingham JG. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 92: 2934-2940, 1993.
36. Rasband WS. ImageJ (1.6 ed.). Bethesda, MD: National Institutes of Health, 1997-2010.
37. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 52: 1527-1539, 2008.
38. Ruiz-Hurtado G, Fernandez-Velasco M, Mourelle M, Delgado C. LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension 50: 1049-1056, 2007.
39. Singh RJ, Hogg N, Joseph J, Konorev E, Kalyanaraman B. The peroxynitrite generator, SIN-1, becomes a nitric oxide donor in the presence of electron acceptors. Arch Biochem Biophys 361: 331-339, 1999.
40. Umar S, van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem 333: 191-201, 2010.
41. Unger P, Leone A, Staroukine M, Degre S, Berkenboom G. Hemodynamic response to molsidomine in patients with ischemic cardiomyopathy tolerant to isosorbide dinitrate. J Cardiovasc Pharmacol 18: 888-894, 1991.
42. Vandenbossche GM, De Muynck C, Colardyn F, Remon JP. Light stability of molsidomine in infusion fluids. J Pharm Pharmacol 45: 486-488, 1993.
43. Varma SK, Owen RM, Smucker ML, Feldman MD. Is tau a preload-independent measure of isovolumetric relaxation? Circulation 80: 1757-1765, 1989.
44. Vercauteren SR, Ysebaert DK, De Greef KE, Eyskens EJ, De Broe ME. Chronic reduction in renal mass in the rat attenuates ischemia/reperfusion injury and does not impair tubular regeneration. J Am Soc Nephrol 10: 2551-2561, 1999.
45. Wesseling S, Koeners MP, Kantouh F, Joles JA, Braam B. Consequences of perinatal treatment with L-arginine and antioxidants for the renal transcriptome in spontaneously hypertensive rats. Pflugers Arch 458: 513-524, 2009.
46. Wilson RM, De Silva DS, Sato K, Izumiya Y, Sam F. Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. Hypertension 54: 583-590, 2009.
47. Wyatt HL, Meerbaum S, Heng MK, Gueret P, Corday E. Cross-sectional echocardiography. III. Analysis of mathematic models for quantifying volume of symmetric and asymmetric left ventricles. Am Heart J 100: 821-828, 1980. (Pubitemid 11198874)
48. Zoccali C, Benedetto FA, Tripepi G, Mallamaci F, Rapisarda F, Seminara G, Bonanno G, Malatino LS. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. J Am Soc Nephrol 17: 1460-1465, 2006.